Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Current Leases (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Current Leases data on record, last reported at $341000.0 in Q4 2025.

  • For Q4 2025, Current Leases rose 8.25% year-over-year to $341000.0; the TTM value through Dec 2025 reached $341000.0, up 8.25%, while the annual FY2025 figure was $341000.0, 8.25% up from the prior year.
  • Current Leases reached $341000.0 in Q4 2025 per VRCA's latest filing, up from $335000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $679000.0 in Q1 2024 and bottomed at $6000.0 in Q4 2021.
  • Average Current Leases over 5 years is $293100.0, with a median of $312000.0 recorded in 2023.
  • Peak YoY movement for Current Leases: soared 4850.0% in 2022, then plummeted 52.72% in 2025.
  • A 5-year view of Current Leases shows it stood at $6000.0 in 2021, then skyrocketed by 4850.0% to $297000.0 in 2022, then increased by 26.6% to $376000.0 in 2023, then fell by 16.22% to $315000.0 in 2024, then grew by 8.25% to $341000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $341000.0 in Q4 2025, $335000.0 in Q3 2025, and $318000.0 in Q2 2025.